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(UK) -4.8 (Spain)) vs. 3.2 (1.5 (Germany) -6.6 (Spain), VAS score: 3.8 (range: 3.0 (UK) 
-4.8 (Italy)) vs. 3.1 (range: 1.9 (Germany) -3.9 (Italy)). ConClusions: Among RA 
patients receiving adalimumab or etanercept monotherapy, disease severity was 
similar across the EU5, with patients in Spain and France having relatively lower, 
and patients in Italy, Germany, and UK having relatively higher burden and poorer 
treatment response. Factors influencing the observed patterns of geographic vari-
ation warrant further scrutiny to optimize therapeutic interventions and improve 
outcomes.
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objeCtives: We evaluated the effectiveness of traditional disease-modifying 
antirheumatic drugs (tDMARDs) and novel DMARDs, alone and in combination, 
in methotrexate- and biologic-naive adults with moderate to severe early rheu-
matoid arthritis (ERA; < 3-year duration). Methods: Literature review identified 
randomized controlled trials (RCTs) of tDMARDs and novel DMARDs reporting 
efficacy outcomes (American College of Rheumatology [ACR] 20/50/70/90 response 
and Disease Activity Score at 28 joints [DAS28] remission). Data were pooled using 
Bayesian network meta-analysis techniques. For ACR response, data were analyzed 
using a fixed-effects ordered probit model, which makes efficient use of ordered 
categorical data and guarantees coherent prediction of multinomial response prob-
abilities. For DAS28 remission, data were analyzed with a fixed-effects binomial 
logit model. Sensitivity analyses tested the effects of grouping treatments by class 
and broadening/narrowing inclusion criteria. Results: Results from a synthesis 
of 16 RCTs of tDMARDs (methotrexate, sulfasalazine, hydroxychloroquine) and 
novel DMARDs (biologics [abatacept, adalimumab, etanercept, infliximab, goli-
mumab, tocilizumab] and tofacitinib) indicated that biologics+methotrexate, triple 
tDMARDs, and tocilizumab and tofacitinib monotherapy significantly increased 
response across all ACR categories versus methotrexate. ACR response probabilities 
for biologics+methotrexate were not significantly different between agents. ACR 
response probabilities to novel DMARD monotherapy varied, trending toward higher 
values for tofacitinib and tocilizumab than etanercept or adalimumab. In studies 
reporting DAS28 remission, treatment with tofacitinib or biologics±methotrexate, 
except adalimumab alone, improved remission likelihood versus methotrexate. 
Tocilizumab±methotrexate generated the highest probability of remission among 
biologics and was significantly more effective than other biologics±methotrexate 
and tofacitinib. Results across outcomes were robust to alternative grouping of 
interventions and change in inclusion criteria. ConClusions: Based on ACR 
response, the expected efficacy of biologics+methotrexate, tofacitinib and tocili-
zumab monotherapy, and triple tDMARD therapy appeared higher than MTX in 
ERA. Tocilizumab±methotrexate was expected to have the highest probability 
of generating DAS28 remission and was significantly more effective than other 
biologics±methotrexate and tofacitinib.
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objeCtives: This study aims to provide estimates of EQ-5D as a function of Health 
Assessment Questionnaire – Disability Index (HAQ-DI) scores in patients with 
rheumatoid arthritis (RA) in Taiwan. Methods: Face-to-face patient interviews 
on a total of 140 patients aged between 30 and 70 years old were recruited at the 
rheumatology outpatient clinics of four hospitals located in northern, central and 
southern Taiwan during June 2013-May 2014. The severity distribution of patients 
was mild RA (Disease Activity Score [DAS 28] < 3.2) (N= 57), moderate RA (3.2□…
DAS< 5.1) (N= 44), and severe RA (DAS≥ a5.1) (N= 39). Socio-demographic and clinical 
information were collected, and the HAQ-DI and the EQ-5D questionnaires were 
completed. Generalized linear regression models were used to predict EQ-5D util-
ity values as functions of HAQ-DI scores, age, and gender. Results: Patient mean 
age was 50.8 years old (standard deviation [SD], 11.3 years); 81.4% of the patients 
were women and mean disease duration was 9.65 years (SD, 6.84 years). HAQ-DI 
< 0.5, 58%; 0.5□…HAQ-DI< 1.1, 16%; 1.1□…HAQ-DI< 1.6, 9%, 1.6□… HAQ-DI< 2.1, 12%; 
and HAQ-DI≥ a2.1, 4%. HAQ-DI and EQ-5D mean scores were 12.01 (SD, 7.8) and 0.67 
(SD, 0.34), respectively. The models were able to predict actual EQ-5D across the 
range of the HAQ DI. Age and gender were found to be significant determinants in 
estimating the utility functions. ConClusions: Utility values have very often not 
been assessed in the data collection process in a clinical trial. This study showed 
that HAQ-DI scores can be used to derive EQ-5D utility values for patients with RA 
in Taiwan to facilitate conducting a cost-utility analysis.
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objeCtives: Patient age is one of many potential risk factors for fracture nonunion. 
We evaluate impact of age on heal rate (HR) in patients with fresh fracture (≤ 90 
days old). Our hypothesis is that age is not a risk factor for nonunion if fractures 
are treated with LIPUS. Methods: A LIPUS device was approved in 1994 to acceler-
ate fresh fracture healing, though the FDA required a Post-Market Registry. Patient 
data were collected from October 1994 until October 1998 and were reviewed and 
for patients who do not respond to traditional disease modifying anti-rheumatic 
drugs (DMARDs). This study aimed to compare the efficacy of biological agents with 
traditional DMARDs for methotrexate (MTX) treatment failure patients. Methods: 
Four DMARDs (hydroxychloroquine, sulfasalazine, methotrexate, leflunomide) and 
five anti-TNF drugs (adalimumab, etanercept, golimumab, infliximab, certolizumab) 
were selected according to expert consensus. A systematic search of the published 
systematic reviews was performed including MEDLINE, EMBASE and Cochrane 
Library. Among the identified 52 systematic reviews, 3 systematic reviews were 
finally selected and updated to July 2013. Data extraction and methodological qual-
ity assessment using Cochrane Risk of Bias was performed in pairs. Comparative 
efficacy was analyzed using Baysian mixed treatment comparison (MTC). Results: 
A total of 85 trials from 7,938 citations were included. Nineteen trials were grouped 
as MTX failure patients (mean age: 52.9 years, mean of rheumatoid factor posi-
tive rate: 76.6%). Nine studies were included in the analysis of Health Assessment 
Questionnaire (HAQ). The best treatment was certolizumab combined with MTX (MD 
-0.40,95% CrI -0.95 to 0.13). For comparative effects on DAS 28-ESR < 2.6 (remission), 
4 trials were included in analysis. The best treatment was golimumab combined 
with MTX (OR 24.5, 95% CrI 3.51 to 99.52). For comparative effects on ACR 70, the best 
treatment was certolizumab combination with MTX (OR 10.46, 95% CrI 3.66 to 24.41) 
in 11 trials. ConClusions: In the MTX failure patients, certolizumab combination 
with MTX lowered HAQ score than MTX. The result of DAS 28- ESR< 2.6 (remission), 
golimumab combined with MTX was the most effective treatment. Certolizumab 
combined with MTX was best treatment for the ACR 70 response.
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objeCtives: Quality of Life (QoL) is important for patients with RA and Enbrel® has 
demonstrated QoL benefits in this patient group. HD203 is an etanercept biosimilar, 
which reported pharmacokinetic bioequivalence to the reference product Enbrel® 
in a Phase I trial and, more recently, demonstrated equivalent efficacy and compa-
rable safety in a phase III randomized trial in Korean patients with RA. Assessing 
QoL was a secondary objective of the HERA study, the results of which are reported 
here. Methods: Patients (male or female aged ≥ 20 years) with active RA were 
randomized (1: 1) to 25 mg HD203 or Enbrel®, administered subcutaneously twice 
weekly with MTX for 48 weeks. QoL assessments (Short Form 36, SF-36; Functional 
Assessment of Chronic Illness Therapy-Fatigue, FACIT-F; EuroQol-5 dimension, 
EQ5D) were undertaken at weeks 24 and 48. Results: In total, 294 patients were 
randomized (147 to HD203; 147 to Enbrel®). There was no significant difference 
between groups on QoL assessments at baseline. QoL assessments were similar 
for HD203 and Enbrel® at week 24 and 48 overall. However, SF-36 Role Emotional 
and Bodily Pain subscales showed significant increase in favour of HD203 at week 
24 (p= 0.0252) and week 48 (p= 0.0243) respectively. No significant difference was 
observed between HD203 and Enbrel® for FACIT-F scores at week 24 or 48, except at 
week 48 for the Emotional Well-being domain, which was significantly improved 
with Enbrel® vs. HD203 (p= 0.0360). No significant differences between groups in 
EQ5D scores were observed at any time. ConClusions: Together with previous 
reports of equivalent pharmacokinetics and efficacy, and comparable safety, these 
data support the biosimilarity of HD203 vs. Enbrel®.
PMS9
cOMPariSON Of DiSEaSE StatuS aND OutcOMES Of PatiENtS With 
rhEuMatOiD arthritiS (ra) rEcEiviNg aDaliMuMab Or EtaNErcEPt 
MONOthEraPy iN EurOPE
Narayanan S1, Lu Y.2, Hutchings R.2, Baynton E.2, Hautamaki E.1
1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK
objeCtives: To compare the disease status and outcomes of patients with RA 
receiving adalimumab and etanercept monotherapy in Europe. Methods: A 
multi-country, multi-center medical chart-review study of RA patients was con-
ducted among rheumatologists in UK/France/Germany/Italy/Spain to collect de-
identified data on patients who were recently treated with a biologic as part of 
usual care. Physicians were screened for duration of practice (3-30 yrs) and patient 
volume (incl. > 5 RA biologic patients/month) and recruited from a large panel to 
be geographically representative in each country. Eligible patient charts (≥ 3) were 
randomly selected from a sample of prospective patients visiting each center/prac-
tice during the screening period. Physicians abstracted patient diagnosis, treat-
ment patterns/dynamics and patient symptomatology/disease status/outcomes. 
Patients on adalimumab/etanercept monotherapy were analyzed. Results: 428 
eligible RA patient charts were abstracted; 152 on adalimumab (female: 68%, age: 
52.1yrs, average months on adalimumab: 22.8, 90% on first biologic) and 142 on 
etanercept (female: 70%, age: 50.5yrs, average months on etanercept: 24.6, 97% 
on first biologic). Among patients with available data, latest lab measures docu-
mented were (adalimumab vs. etanercept): ESR: 21.0mm/h (range: 16.1 (UK) -24.6 
(Germany)) vs. 23.4mm/h (range: 13.5 (France) -29.8 (Italy)), CRP: 9.9mg/dl (range: 
5.0 (Italy) -17.0 (Germany)) vs. 13.1mg/dl (range: 7.7 (France) -15.6 (Italy)), rheu-
matoid factor-positive: 81% (range: 68% (Germany) -86% (Spain)) vs. 85% (range: 
62% (Germany) -95% (Spain)), and anti-CPP-positive: 69% (range: 47% (Germany) 
-83% (France)) vs. 74% (range: 61% (Spain) -83% (France)). Latest disease severity 
measures documented were (adalimumab vs. etanercept): Swollen Joint Counts: 
2.7 (range: 2.2 (Spain) -3.5 (Germany)) vs. 2.6 (range: 0.7 (Spain) -6.3 (UK)), Tender 
Joint Counts were 3.9 (range: 3.2 (France) -5.1 (Germany)) vs. 3.7 (range: 1.5 (Spain) 
-7.1 (UK)), Health Assessment Questionnaire (HAQ) rating: 1.6 (range: 0.1 (Spain) 
-2.3 (Germany)) vs. 1.4 (0.3 (Spain) -2.5 (Germany), DAS28 score: 3.8 (range: 2.5 
